Leptomeningeal Metastases: Diagnosis and Evaluation

Imaging Characteristics

• The combination of supratentorial/spinal ependymal enhancement with infratentorial leptomeningeal enhancement is a characteristic pattern of meningeal carcinomatosis 1, 2, 3

• Leptomeningeal enhancement typically appears as linear or nodular deposits coating cranial and spinal nerves, cerebral sulci, cerebellar folia, and spinal cord 4

• Linear ependymal enhancement is one of the characteristic MRI findings of leptomeningeal metastases 2, 3

• Multi-level distribution (supratentorial, infratentorial, and spinal) is typical of CSF dissemination 1, 3

• Post-contrast T1 and post-contrast FLAIR sequences are the most sensitive for detecting leptomeningeal metastases 2, 3

• MRI sensitivity for leptomeningeal metastases is 66-98% and specificity is 77-97.5% 2, 3

MRI Protocol Requirements

• Brain and complete spine MRI with contrast should be performed before any lumbar puncture to avoid nonspecific post-procedural meningeal enhancement 1, 2

• Brain sequences should include: axial T1, axial FLAIR, axial diffusion, axial T2, 3D post-gadolinium T1, and 3D post-gadolinium FLAIR 1, 2

• Spinal sequences should include: post-gadolinium sagittal T1, sagittal T1 without contrast, sagittal T2 with fat suppression, and axial T1 with contrast in regions of interest 1, 2

• Slice thickness should be 1 mm to detect small deposits 1

CSF Analysis Protocol

• CSF cytology is the gold standard for confirming leptomeningeal metastases 1, 2, 3

• Ideal CSF volume is >10 mL, minimum 5 mL 1, 2

• CSF should be processed within 30 minutes or fixed with ethanol/Carbowax (1:1 ratio) 1, 2

• Routine staining includes Papanicolaou and Giemsa 1, 2

• Additional immunocytochemistry for epithelial and melanocytic markers should be performed as indicated 1, 2

• If the first CSF sample is negative, a second CSF sample should be analyzed 1, 2

• Nonspecific CSF findings include: elevated opening pressure (>200 mm H₂O), increased leukocytes (>4/mm³), elevated protein (>50 mg/dL), and decreased glucose (<60 mg/dL) 1

Primary Tumor Evaluation

• History of known cancer should be evaluated, with breast cancer, lung cancer, and melanoma being the most common primary sources 1, 4

• If no known primary tumor exists, chest-abdomen-pelvis CT and PET-CT should be performed 1

• FDG-PET-CT is rarely useful for diagnosing leptomeningeal metastases per se 1

Differential Diagnosis Considerations

• In Bing-Neel syndrome (lymphoplasmacytic lymphoma), leptomeningeal enhancement may be diffuse or tumoral 5

• Neurosarcoidosis can show extensive leptomeningeal enhancement, especially at the skull base 3, 6

• Supratentorial ependymomas are rare and typically present as well-circumscribed masses with heterogeneous enhancement 7

• Ependymomas require staging with craniospinal MRI and CSF cytology due to risk of dissemination 7

Pattern Recognition for Alternative Diagnoses

• Extensive leptomeningeal enhancement at the skull base suggests neurosarcoidosis or granulomatous diseases 6

• Punctate or miliary enhancement suggests CLIPPERS, vasculitis, progressive multifocal leukoencephalopathy, or Susac syndrome 6

• Band-like enhancement suggests Baló's concentric sclerosis 6, 8

• "Cloud-like" enhancement suggests neuromyelitis optica spectrum disorders 6, 8

• "Trident sign" (subpial enhancement + central spinal canal) suggests neurosarcoidosis 6

Prognostic Factors

• Presence of communicating hydrocephalus (11-17% of patients) indicates CSF flow obstruction and worse prognosis 1

• CSF flow studies with tracers (¹¹¹Indium-DTPA or ⁹⁹Technetium) should be considered if intrathecal therapy is planned, as 61-70% have flow abnormalities 1

Management Algorithm

• MRI must be performed BEFORE lumbar puncture to avoid nonspecific post-procedural enhancement 1, 2

• CSF cytology should be obtained with adequate volume (>10 mL) and rapid processing (<30 min) 1, 2

• If cytology is negative, lumbar puncture should be repeated for a second sample 1, 2

• Primary tumor should be identified or searched for through clinical history and whole-body imaging 1

• Evaluation for hydrocephalus should be performed and shunting considered if present 1

• Specific treatment should be initiated according to the primary tumor once diagnosis is confirmed 1, 3

Imaging Recommendations for Suspected Leptomeningeal Metastases

Diagnostic Accuracy

• Diffuse linear leptomeningeal enhancement is the most common imaging pattern of leptomeningeal metastases, whereas isolated nodular deposits are less frequent. 9
• Contrast‑enhanced MRI with gadolinium has a sensitivity of 66 %–98 % and specificity of 77 %–97.5 % for detecting leptomeningeal disease, far surpassing contrast‑enhanced CT. 10
• Post‑contrast T1‑weighted and FLAIR MRI sequences provide the highest sensitivity for identifying leptomeningeal involvement. 10
• Three‑dimensional T1 post‑contrast images acquired with 1 mm slice thickness reveal small meningeal deposits that are typically invisible on CT. 11
• MRI uniquely visualizes a range of enhancement patterns—including sulcal, linear ependymal, cranial‑nerve‑root, and nodular cauda‑equina involvement—facilitating comprehensive disease assessment. 9
• Whole‑brain and total‑spine MRI is the preferred imaging modality over CT because of its superior spatial resolution and ability to detect both focal and diffuse leptomeningeal disease. 11
• In patients with clinical features suggestive of leptomeningeal metastases (e.g., headache, cranial‑nerve palsy, radicular pain, cauda‑equina syndrome), a contrast‑enhanced CT will miss the majority of cases; MRI should be obtained directly. 9

Clinical Management

• A negative contrast‑enhanced CT does not exclude leptomeningeal disease; when clinical suspicion remains high, an immediate contrast‑enhanced MRI of the brain and entire spine is warranted. 11

Recommended MRI Protocol

• Field strength: Minimum 1.5 Tesla, preferably 3 Tesla to maximize signal‑to‑noise ratio. 10
• Brain sequences: Axial T1, axial FLAIR, axial diffusion‑weighted imaging, axial T2, 3‑D post‑gadolinium T1, and 3‑D post‑gadolinium FLAIR. 10
• Spine sequences: Post‑gadolinium sagittal T1, sagittal T1 without contrast, sagittal T2 with fat suppression, and axial T1 with contrast targeted to areas of interest. 10
• Slice thickness: 1 mm for all 3‑D post‑contrast acquisitions to detect minute meningeal deposits. 11

Diagnostic Workup and Initial Management of Leptomeningeal Disease

Imaging Protocol (EANO‑ESMO guideline)

• Perform a contrast‑enhanced brain and total‑spine MRI before any lumbar puncture to avoid post‑procedural meningeal enhancement that can obscure disease. Use a minimum field strength of 1.5 T (3 T preferred) with gadolinium 0.1 mmol/kg injected 10 minutes prior to acquisition. Include brain sequences (axial T1, axial FLAIR, axial diffusion, axial T2, 3D post‑gadolinium T1, 3D post‑gadolinium FLAIR) and spine sequences (post‑gadolinium sagittal T1, sagittal T1 non‑contrast, sagittal T2 with fat suppression, axial T1 with contrast in regions of interest). Slice thickness must be 1 mm to detect small meningeal deposits. Post‑contrast T1‑weighted and FLAIR sequences provide the highest sensitivity (66–98 %) for leptomeningeal disease, far superior to CT imaging. 12

CSF Cytology and Laboratory Processing (EANO‑ESMO guideline)

• Collect ≥10 mL of CSF (minimum 5 mL) for cytology to maximize diagnostic yield; process fresh samples within 30 minutes or fix immediately with ethanol/Carbowax (1:1). Perform routine Papanicolaou and Giemsa staining, and add immunocytochemical stains for epithelial and melanocytic markers when material permits. If the first sample is negative, obtain a second lumbar puncture, as sensitivity improves with repeat sampling. 68–97 % of patients with confirmed leptomeningeal disease have positive MRI findings, underscoring the importance of high‑quality imaging alongside cytology. [12][13]

Enhancement Pattern Classification (EANO‑ESMO guideline)

• Type A (Linear): Sulcal, linear ependymal, or cranial‑nerve‑root enhancement.
• Type B (Nodular): Leptomeningeal nodules ≥5–10 mm (orthogonal diameters), especially in the cauda equina.
• Type C (Combined): Co‑existence of linear and nodular patterns.
• Type D (Hydrocephalus only): No direct leptomeningeal enhancement; may present with communicating hydrocephalus.

Standardized Neurological Examination (EANO‑ESMO guideline)

• Document typical signs: headache, nausea/vomiting, altered mental status, gait disturbance.
• Assess cranial‑nerve dysfunction (diplopia, visual changes, hearing loss).
• Evaluate sensorimotor deficits of the extremities, cauda equina syndrome, and radicular neck/back pain.
• Grade neurological deficits to establish a baseline for monitoring treatment response. [12][13]

Identification of Primary Malignancy and Ancillary Imaging (EANO‑ESMO guideline)

• When no known primary tumor exists, obtain chest‑abdomen‑pelvis CT and FDG‑PET‑CT; however, FDG‑PET‑CT is rarely useful for directly diagnosing leptomeningeal metastases. 14

Prognostic Factors (EANO‑ESMO guideline)

• Unfavorable factor: Presence of communicating hydrocephalus, observed in 11–17 % of patients with leptomeningeal disease. 14

Pitfalls and Differential Diagnosis (EANO‑ESMO guideline)

• Post‑procedural meningeal enhancement can occur after recent lumbar puncture or ventricular shunt placement; recognize this to avoid false‑positive interpretation. [12][14]